Novo signs up for Crucell's STAR tech
Dutch biotech Crucell last week announced it had signed a research licence agreement with Novo Nordisk for the company's STAR technology.
Archives for January 22, 2007
AZ invests a further $100m in Boston
AstraZeneca (AZ) has continued its pipeline consolidation by investing a further $100m (€77m) in its Boston research centre, which focuses on treatments for infectious diseases and cancer.
Sweet toothed bacteria combat gut disorders
Researchers at the University of Leeds have genetically modified a common gut bacterium to respond to a sugar and produce a treatment for Inflammatory Bowel Disease (IBD).
Workhorse analytical tools to reduce human errors
Agilent Technologies has signed an agreement with Groton Biosystems to co-market measuring solutions for the pharmaceutical industry, as the Process Analytical Technology (PAT) initiative gains popularity among drug manufacturers constantly looking...
SciGen aims for a share of the multibillion hep B vaccine market
Biopharmaceutical firm SciGen has invested $30m (€23.2m) in a hepatitis B vaccine manufacturing plant in Israel, expecting to capture up to 15 per cent of the global market during a three year period.
Breakthrough in controlled release drug delivery
New French research into biodegradable polymers is opening up the door to controlled release treatments for a broader range of drugs, potentially doing away with traditional delivery methods of a variety of drugs.
RNA 'switch' could turn off cancer
Scientists have discovered a piece of 'junk' genetic material that could switch off cancer tumours, preventing them from growing.
Cellartis channels Scottish expertise in stem cells
Cellartis has begun a new research programme in Scotland as part of a £9.5m (€14.5m) programme by ITI Life Sciences to develop the world's first automated process to produce high-quality human stem cells.